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Muscarinic acetylcholine receptorThe discovery of allostericmodulators of G protein-coupled receptors (GPCRs) provides a promisingnew strategy
with potential for developing novel treatments for a variety of central nervous system (CNS) disorders. Tradition-
al drug discovery efforts targeting GPCRs have focused on developing ligands for orthosteric sites which bind en-
dogenous ligands. Allosteric modulators target a site separate from the orthosteric site to modulate receptor
function. These allosteric agents can either potentiate (positive allosteric modulator, PAM) or inhibit (negative
allosteric modulator, NAM) the receptor response and often provide much greater subtype selectivity than
orthosteric ligands for the same receptors. Experimental evidence has revealed more nuanced pharmacological
modes of action of allosteric modulators, with some PAMs showing allosteric agonism in combination with pos-
itive allosteric modulation in response to endogenous ligand (ago-potentiators) as well as “bitopic” ligands that
interact with both the allosteric and orthosteric sites. Drugs targeting the allosteric site allow for increased drug
selectivity and potentially decreased adverse side effects. Promising evidence has demonstrated potential utility
of a number of allosteric modulators of GPCRs in multiple CNS disorders, including neurodegenerative diseases
such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, as well as psychiatric or neurobehav-
ioral diseases such as anxiety, schizophrenia, and addiction.
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agents for the treatment of debilitating CNS diseases, which affect mil-
lions of people worldwide. While the discovery and development of
new therapeutic agents are challenging for all therapeutic areas, CNS
drug discovery efforts have been especially challenging and have a
very high attrition rate (Kola and Landis, 2004). The GPCRs have been
among the most fruitful targets for developing drugs for the treatment
of CNS disorders, as well as range of other human disease states. Many
current clinical therapeutic agents act by targeting this important recep-
tor class and downstream signaling pathways (Allen and Roth, 2011;
Fang et al., 2003;Melancon et al., 2012). However, somemajor subfam-
ilies of GPCRs have proven intractable in drug discovery efforts because
of a difﬁculty in achievinghigh subtype selectivity anddrug-like proper-
ties, including high CNS exposure, that are critical for advancing novel
agents for the treatment of neurological and psychiatric disorders.
Historically, drug discovery efforts targeting GPCRs have focused on
the development of traditional agonists and antagonists that interact
with the orthosteric neurotransmitter binding site to either mimic or
block the action of the endogenous neurotransmitter or agonist. While
this has been fruitful, there are many instances where the high conser-
vation of the orthosteric binding site across related receptors prevents
the development of subtype selective agents. Also, developing drug
candidates based on the chemical scaffolds of the endogenous ligand
may raise challenges in establishing appropriate proﬁles in terms of
pharmacokinetic properties or brain exposure.
In recent years, advances in the development of allosteric modula-
tors of GPCRs have emerged as promising new approaches for develop-
ing therapeutic agents that may be useful for the treatment of CNS
disorders. Allosteric modulators of GPCRs bind to sites that are separate
from the orthosteric binding site of the endogenous ligand and are often
less highly conserved than the orthosteric site (Conn et al., 2009a). For
some GPCRs, this has allowed optimization of allosteric modulators
that achieve much greater subtype selectivity than is possible with tra-
ditional orthosteric ligands. In addition, allosteric modulators have
other potential advantages, including ability to develop agents that
have functional selectivity, allowing for potential targeting of select
downstream signaling pathways, and a greater diversity of chemical
scaffolds that can facilitate efforts to optimize pharmacokinetic and
other drug-like properties of potential drug candidates. The surge in
the development of allosteric agents has revealed a varied repertoire
of drug activities, including PAMs andNAMs aswell as agentswith com-
bined allosteric agonist and PAM activity and neutral ligands, termed
silent allosteric modulators (SAMs) that bind to the allosteric site but
do not potentiate or inhibit responses to the endogenous agonist (see
Conn et al., 2009a; Melancon et al., 2012; Niswender and Conn, 2010
for reviews). In addition, allosteric agonists with a bitopic bindingmode (binds to both the allosteric site and the orthosteric site) have
been identiﬁed (Digby et al., 2012a; Lebon et al., 2009; Spalding et al.,
2002). These varied modes of action provide tools for experimental in-
vestigation into GPCR structure and function. To date, there is awide va-
riety of allosteric modulators that are showing promise for potential
treatment of CNS diseases (Conn et al., 2009c). Among these, some of
the most advanced and well understood include allosteric modulators
of the metabotropic glutamate (mGlu) receptors and the muscarinic
acetylcholine receptors (mAChRs). For instance, allosteric modulators
of speciﬁc subtypes ofmGlu receptors have potential utility in the treat-
ment of schizophrenia, autistic spectrum disorders, and Parkinson's
disease (Morin et al., 2013b). Positive allosteric modulators of the M1
and M4 muscarinic receptors show promising applications in both
Alzheimer's disease and schizophrenia. This is an exciting time in CNS
drug discovery with several allosteric modulator candidates moving
from preclinical models into clinical development.Allosteric modulators of GPCRs
GPCRs, also called seven transmembrane spanning receptors
(7TMRs), represent the largest family of cell surface receptors and are
the targets of intense drug discovery efforts. While a number of avail-
able drugs on the market target GPCR signaling pathways, overall less
than 20% of GPCRs are targeted (Allen and Roth, 2011). Ubiquitous
receptors, these seven transmembrane-spanning proteins transduce
extracellular signals for ligands as diverse as ions, photons of light, odor-
ants and peptides into intracellular signaling cascades. Over 800 human
GPCRs have been identiﬁed to date with ﬁve major families (andmulti-
ple subfamilies) based on their amino acid sequences (Katritch et al.,
2013). Despite intense drugdiscovery and development efforts, clinical-
ly useful drugs do not exist for the large majority of these receptors.
As noted above, the orthosteric binding site within GPCR subfamilies
is often highly conserved, making the development of subtype speciﬁc
ligands difﬁcult. Of the orthosteric ligands developed, many of those
with the highest subtype selectivity are antagonists.
Discovery and optimization of novel highly selective allosteric mod-
ulators of GPCRs have opened exciting new opportunities for the devel-
opment of highly selective drug candidates for speciﬁc GPCR subtypes
that were intractable using traditional approaches. While the major
advances in the discovery of allosteric modulators of GPCRs have only
occurred over the past decade, the principle of targeting allosteric sites
on neurotransmitter receptors that act as ligand-gated ion channels
has a long history and has been highly successful in developing agents
for the treatment of CNS disorders (Melancon et al., 2012). The classic
example of an allosteric modulator is the benzodiazepine class, which
are positive allosteric modulators at the GABAA receptors (Mohler
et al., 2002). These agents provide effective treatment of anxiety,
sleep, and seizure disorders without inducing the adverse side effects
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Allosteric modulators have been discovered for GPCRs, enzymes, and
other ion channels (Bogoyevitch and Fairlie, 2007; Burford et al.,
2013; Conn et al., 2009a; Hogg et al., 2005; Kenakin and Miller, 2010;
Lewis et al., 2008; Scott et al., 2009).
As for the ligand-gated ion channels, GPCRs occupied by allosteric li-
gands can be modulated in a positive or negative manner (Conn et al.,
2009a). The interaction of the receptor with an allosteric modulator
can result in multiple pharmacological effects: afﬁnity modulation,
impacting the association–dissociation rate of the orthosteric ligand;
efﬁcacy modulation, affecting orthosteric ligand-induced downstream
signaling responses; and agonism/inverse agonism, affecting receptor
signaling in a positive or negative manner either in the presence or
absence of orthosteric ligand. Ternary complex models that use
cooperativity to quantify the allosteric effects are useful conceptually,
but have been difﬁcult to ﬁt to experimental data. Using the operational
model of allosterism, it is possible to quantify allosteric drug properties
for use in drug development efforts. The advantages of allosteric modu-
lators include: receptor selectivitywith subtype selectivity and selective
cooperativity at a given subtype aswell as receptor activity dependence
which maintains spatial and temporal activity dependence of endoge-
nous signaling for those ligands which show efﬁcacy only in the
presence of the endogenous orthosteric ligand (Conn et al., 2009a;
Lewis et al., 2008).
Allosteric agents have the potential to show differential effects on
downstream signaling pathways, termed functional selectivity (biased
agonism, stimulus trafﬁcking). For example, mGlu5 activates both intra-
cellular calcium mobilization and extracellular signal-regulated kinase
1/2 (ERK1/2) signaling in rat cortical astrocytes. An early example of
functional selectivity of allosteric modulators of GPCRs came with stud-
ies comparing the effects of the mGlu5 PAMs DFB and CPPHA in native
rat cortical astrocytes. While both showed similar positive modulatory
effects on DHPG-induced intracellular calcium transients, their effects
on ERK1/2 signaling differed (Zhang et al., 2005). There are nowmulti-
ple examples in which allosteric modulators have been identiﬁed that
have differential effects on coupling of the GPCR to different signaling
pathways (Digby et al., 2012a; Kenakin, 2010; Maj et al., 2003;
Mathiesen et al., 2005; Niswender et al., 2010; Noetzel et al., 2013;
Sachpatzidis et al., 2003; Shefﬂer and Conn, 2008; Wei et al., 2003).
Leveraging the functional selectivity of allosteric modulators of GPCRs
provides a potential opportunity to develop agents that selectively
target GPCR signaling pathways critical for therapeutic efﬁcacy without
modulating signaling pathways that lead to adverse effects.
Metabotropic glutamate receptors
Metabotropic glutamate (mGlu) receptors represent promising drug
targets for a variety of psychiatric andneurodegenerative CNSdisorders.
Glutamate, the major excitatory neurotransmitter in the CNS, signals
through both ionotropic andmetabotropic glutamate receptors. Metab-
otropic glutamate receptors modulate cell excitability and synaptic
transmission, as opposed to eliciting fast synaptic responses, which
are mediated by ionotropic glutamate receptors. The metabotropic glu-
tamate (mGlu) receptor family, which couple to intracellular second
messengers through heterotrimeric G-proteins, includes eightmembers
that serve neuromodulatory roles within the CNS. Members of family 3
(or Class C) GPCRs,mGlu receptors are characterized by a large extracel-
lular “venus ﬂytrap” N-terminal region, which serves as the glutamate
(orthosteric) binding site. mGlu receptors are divided into three sub-
groups according to agonist binding, signaling transduction pathways,
and sequence homology. Group I, which includes mGlu1 and mGlu5 re-
ceptors, are coupled to Gq/11 and mediate IP3/Ca2+ signal transduction
(Abe et al., 1992). Group II (mGlu2,3) and Group III (mGlu4,6,7,8) nega-
tively couple to adenylyl cyclase and other effector systems through
Gi/o proteins.While there is abundant sequence homologywithin recep-
tor subgroups at the orthosteric binding site, allosteric ligands bind to aunique topographically distinct site within the transmembrane domain.
The allosteric site contains a higher level of sequence diversity between
receptor subtypes as compared to the orthosteric site, allowing for
greater subtype selectivity of allosteric ligands (Christopoulos and
Kenakin, 2002; Conn et al., 2009a). mGlu receptors are expressed in
neurons and glial cells, including astrocytes, oligodendrocytes, and mi-
croglia. In neurons, mGlu1 and mGlu5 are expressed postsynaptically,
modulating cell excitability and post-synaptic efﬁcacy whereas
mGlu2,3,4,7,8, are predominately expressed presynaptically, where they
can regulate neurotransmitter release (Conn and Pin, 1997). The CNS
therapeutic targets for mGlus that have received the most attention in-
clude Parkinson's disease, Fragile X syndrome/autism spectrum disor-
ders, schizophrenia, cognition, addiction, depression, anxiety and pain.
Parkinson's disease
Parkinson's disease (PD) is a chronic neurodegenerative disorder
characterized bymotor symptomsof rigidity, bradykinesia, tremor, pos-
tural instability and gait disturbance (Jankovic, 2008). Associated non-
motor symptoms include cognitive decline,mood and sleep disturbance
(Chaudhuri et al., 2006). The incidence of PD in patient's older than
55 years is approximately 1% worldwide, creating a substantial disease
burden in the agingworld population. The pathology observed in PDpa-
tients includes progressive degeneration of dopamine neurons in the
substantia nigra pars compacta (SNc) with resulting dysfunction of
the basal ganglia-thalamocortical motor circuit (Fig. 1) (Dickerson and
Conn, 2012; Johnson et al., 2009; Wichmann and DeLong, 1996; Zhang
et al., 2005). Currently available pharmacological treatments for PD
are aimed at dopamine replacement using L-DOPA or dopamine recep-
tor agonists. While initially effective, dopamine-replacement strategies
have undesired side effects including dyskinesia and have decreased ef-
ﬁcacy over time as the disease progresses (Prashanth et al., 2011). The
basal ganglia deep brain nuclei are central to the control of motor func-
tion, and the group III mGlus, includingmGlu4 (Bradley et al., 1999), are
expressed in neurons of different basal ganglia nuclei. Dopamine (DA)
depletion associated with PD in the nigrostriatal pathway leads to hy-
peractivity of inhibitory projections from the striatum to the globus
pallidus, the ﬁrst synapse in the basal ganglia “indirect pathway”
(Hirsch et al., 2000). This glutamatergic overactivity of the indirect
pathway is thought to contribute to the motor dysfunction (Blandini
et al., 2000) and DA neuronal loss (Greenamyre and O'Brien, 1991;
Przedborski, 2005) in PD patients. Clinical and preclinical studies in PD
patients and animal models of PD suggest that decreasing the patholog-
ic overactivity of this indirect pathwaymay be beneﬁcial in reducing the
motor symptoms associated with PD. The Group III mGlus (mGlu4,
mGlu7, mGlu8) are expressed presynaptically at different synapses in
the basal ganglia circuit and are promising targets for PD (Conn et al.,
2005). Of particular relevance, mGlu4 is expressed presynaptically at
the striato-pallidal synapse and reduces GABAergic transmission,
which is overactive in PD patients following loss of dopamine neurons.
ThemGlu4 PAMs are hypothesized to act by reducing activitywithin the
indirect pathway (Johnson et al., 2009). Interestingly, the mGlu4
subtype of mGlu receptor is expressed in presynaptic terminals of
striato-pallidal projections and activation ofmGlu4with the group III se-
lective agonist L-AP4 decreases transmission at the striato-pallidal syn-
apse by inhibiting neurotransmitter release from presynaptic terminals
(Bogenpohl et al., 2013; Matsui and Kita, 2003; Valenti et al., 2003b,
2005). This effectwas absent inmGlu4 knockoutmice, conﬁrming a crit-
ical role for mGlu4. Additionally, L-AP4 and other mGlu4 receptor ago-
nists reverse motor symptoms in preclinical rodent models of PD
(Konieczny et al., 2007; MacInnes et al., 2004; Sibille et al., 2007;
Valenti et al., 2003b).
The discovery of the mGlu4-selective PAMs, including PHCCC (Maj
et al., 2003; Marino et al., 2003) and multiple more highly optimized
agents (Bennouar et al., 2013; Celanire and Campo, 2012; East et al.,
2010; Jimenez et al., 2012; Jones et al., 2011, 2012a; Niswender et al.,
Fig. 1.Basal ganglia circuit. The basal ganglia are a collection of interconnecteddeepgray subcortical nuclei that are essential in the control ofmotor function. Themajor input nucleus of the
basal ganglia is the striatum (caudate and putamen). The cerebral cortex sends stimulatory inputs to the striatum, including primary motor cortex. The major output nuclei include the
substantia nigra pars reticulata (SNr) and the internal globus pallidus (GPi). Two major parallel pathways project from the striatum to the major output nuclei of the basal ganglia. The
direct pathway contains inhibitory projections from the striatum to the output nuclei. GABAergic neurons in the striatum that express D1 dopamine receptors project to the SNr and
GPi. The indirect pathway is polysynaptic, and ends in excitatory projections to the output nuclei from the subthalamic nucleus (STN). GABAergic neurons in the striatum that express
D2 dopamine receptors project to the external globus pallidus (GPe), and subsequently the GPe sends inhibitory projections to the STN. The result of disruption of the indirect pathway
is disinhibition of the STN, and net increased excitatory stimulation to the output nuclei. The balanced activity between the direct pathway inhibition of the output nuclei and the indirect
pathway excitation is essential for the normal control of motor activity. The action of dopamine in the striatum decreases transmission through the indirect pathway and increases trans-
mission through the direct pathway. Loss of dopamine neurons in the substantia nigra pars compacta (SNc) in PD leads to decreased inhibitory tone in the direct pathwaywith subsequent
increased stimulatory tone in the indirect pathway, increasedGABAergic tone at the thalamus and reduced excitation of themotor cortex.Metabotropic glutamate receptors are expressed
throughout the basal ganglia. The Group I receptors (mGlu1 and mGlu5) are expressed in multiple locations in the basal ganglia. They are located post-synaptically, and inhibit the basal
ganglia response to dopamine. Group II receptors (mGlu2/3) are located presynaptically to the cortico-striatal, STN-SNr, and STN-SNc synapses. Of the Group III receptors, mGlu4 is known
to modulate corticostriatal, STN-SNr, as well as intrastriatal GABAergic synapses. Cholinergic systemsmodulate basal ganglia function. Of primary importance, tonically active cholinergic
interneurons in the striatum release acetylcholine to modulate basal ganglia and motor function. They act project to neighboringmedium spiny neurons in the striatum. Muscarinic ace-
tylcholine receptors are expressed in the basal ganglia.M1,M2, M4 receptors are expressed in the striatum,withM5 receptors expressed on dopaminergic neurons in the ventral tegmental
area (VTA) and SNc.M4 receptors colocalizewith D1 expressing neurons in the striatum. The development of subtype speciﬁc allostericmodulators of muscarinic ACh receptors will allow
for further characterization of their location and function in the basal ganglia circuit. Adapted from Dickerson and Conn, 2012; Johnson et al., 2009; Conn et al., 2005, andWichmann and
DeLong, 1996.
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aimed at testing the hypothesis thatmGlu4 PAMsmay have utility in re-
ducing motor symptoms in PD patients (Dickerson and Conn, 2012;
Engers et al., 2009; Hopkins et al., 2009; Konieczny et al., 2007).
Interestingly, multiple structurally diverse mGlu4-selective PAMs have
robust efﬁcacy in reducingmotor disability in a range of rodentmodels,
including haloperidol-induced catalepsy and both unilateral and
bilateral lesions of DA neurons using 6-OHDA (Bennouar et al., 2013;
Engers et al., 2010; Jones et al., 2012a; Le Poul et al., 2012; Lopez et al.,
2007; MacInnes et al., 2004; Marino et al., 2003; Taylor et al., 2003).
Furthermore, the systemically active mGlu4 PAMs VU0364770 (Jones
et al., 2012a) and ADX88178 (Celanire and Campo, 2012) potentiate
the antiparkinsonian activity of L-DOPA, showing potential as L-DOPA
sparing agents.
In addition to providing symptomatic relief in PD patients, early data
suggest that mGlu4 PAMs may also show disease modifying effects by
decreasing the degeneration of substantia nigra neurons. Thus, the
mGlu4 PAM PHCCC reduces DA cell death in MPTP-treated WT mice,
while showing no protective effect in mGlu4 knockout mice (Battagliaet al., 2006).While the precisemechanismof this neuroprotective effect
is not clear, it could bemediated by a combination of reduced excitation
of DA neurons (Valenti et al., 2003a), anti-inﬂammatory effects of
mGlu4 activation (Fallarino et al., 2010; Taylor et al., 2003), and other
potential neuroprotective actions on DA neurons (Battaglia et al.,
2006; Bruno et al., 2000). Additionally, the mGlu4 PAM PHCCC as well
as the Group III agonist ACPT-1 show a decrease in rodent models of
neuropathic pain (Goudet et al., 2008), which may be effective for the
non-motor symptoms of PD. Thus, mGlu4 PAMs have potential for
both symptomatic and disease-modifying treatment for PD patients.
WhilemGlu4 PAMs have not advanced to clinical testing, multiple phar-
maceutical companies and academic/industry partnerships are making
exciting progress that may allow direct testing of this hypothesis in
clinical studies (Robichaud et al., 2011).
PD patients chronically treated with L-DOPA require increasing
doses to maintain efﬁcacy and progressively develop L-DOPA-induced
dyskinesia (LID) (Fabbrini et al., 2007; Jenner, 2008; Marsden and
Parkes, 1977; Meissner et al., 2011). Amantadine, an NMDAR antago-
nist, is currently the only drug to show clinical efﬁcacy in LID, and the
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anism resulting in LID is not established, with decreased dopamine
in the basal ganglia in PD,mGlu5 is hypothesized to be involved in com-
pensatory mechanisms and L-DOPA-induced motor complications.
mGlu5 is expressed in the striatum and basal ganglia (Shigemoto et al.,
1993), and basal ganglia levels are increased in 6-OHDA lesioned rats
(Pellegrino et al., 2007), as well as in parkinsonian primates with LID
(Ouattara et al., 2010; Samadi et al., 2008). Preclinical rodent models
of PD show efﬁcacy with mGlu5 NAMs to decrease LID (Dekundy et al.,
2006; Levandis et al., 2008; Mela et al., 2007; Rylander et al., 2009).
Fenobam, an mGlu5 NAM, also decreased LID in both rodent and
primate models of PD (Rylander et al., 2010). The addition of MPEP to
L-DOPA treatment in parkinsonianMPTP lesioned non-human primates
substantially decreased LID both in dyskinetic (Morin et al., 2010) and
de novo lesioned animals (Morin et al., 2013a). Additionally, basal
ganglia [3H]ABP688 speciﬁc binding (mGlu5) was signiﬁcantly less in
primates treated with MPEP combined with L-DOPA compared to L-
DOPA treated animals (Morin et al., 2013b). These studies suggest that
mGlu5 NAMs may be useful as adjunct treatments to L-DOPA for PD.
Currently, the mGlu5 NAMs AFQ056 (Mavoglurant) and ADX48621
(Dipraglurant) (Rylander et al., 2010) are in phase IIa clinical studies
for the treatment of LID in PD. Other possible therapeutic targets for
mGlu5 NAMs in addition to FXS/autism spectrum disorders and LID, in-
clude gastroesophageal reﬂux disease (GERD) (Keywood et al., 2009;
Zerbib et al., 2010), migraine, and anxiety/stress disorders (Swanson
et al., 2005).
It is important to note that the administration of mGlu5 NAMs may
be associated with adverse effects. For instance, the mGlu5 NAM MPEP
exacerbates PCP-induced psychotomimetic and cognition impairment
in animal models (Brody et al., 2004a; Campbell et al., 2004) and early
clinical studies suggest the possibility thatmGlu5 NAMs could have psy-
chotomimetic effects in humans (Friedmann et al., 1980; Itil et al., 1978;
Pecknold et al., 1982). This may be mediated by inhibition of mGlu5-
induced regulation of the NMDA subtype of glutamate receptor (Awad
et al., 2000; Doherty et al., 2000; Henry et al., 2002; Kinney et al.,
2003; Pisani et al., 2001) and the established psychotomimetic effect
of manipulations that inhibit NMDA receptor function (Lahti et al.,
1995; Malhotra et al., 1997). Interestingly, most mGlu5 NAMs have in-
verse agonist activity, which may contribute to this side effect proﬁle
(Porter et al., 2005). However, recent studies have shown that it is pos-
sible to develop mGlu5 NAMs with weak negative cooperativity that
only partially block glutamate activation of mGlu5 with full occupancy
of the receptor (Rodriguez et al., 2005). While in vivo studies with
these partial allosteric antagonists have not been performed, it is possi-
ble that these agents could provide clinical efﬁcacy while minimizing
adverse effects associated with full blockade or inverse agonist activity
at mGlus.
Of interest, A2A adenosine receptors are also expressed in the
striatopallidal neurons and form oligomers with the D2 dopamine re-
ceptor. A2A receptor antagonists are pro-dopaminergic, and therefore
have the potential to reduce the symptoms associated with dopamine
depletion in PD (Kulisevsky and Poyurovsky, 2012). The A2A receptor
antagonist preladenant (SCH412384) delays haloperidol-induced ex-
trapyramidal symptom onset in non-human primates (Varty et al.,
2008). Therefore, the development of A2A NAMs would provide a valu-
able tool for the study of dyskinesia associated with PD and movement
disorders.
In addition to mGlu4 PAMs and mGlu5 NAMs, the development of
mGlu2 and mGlu8 PAMs may be useful for Parkinson's disease therapy.
The Group II mGlus are located presynaptically on glutamatergic axon
terminals in the substantia nigra pars reticulata (SNr), potentially mod-
ulating excitatory neurotransmission (Bradley et al., 2000). Administra-
tion of group II agonists, by either the intracerbroventicular or the
intranigral route, results in a reversal of akinesia in reserpine-treated
rats (Dawson et al., 2000; Murray et al., 2002). Treatment of rat mid-
brain slices with the selective agonist LY379268 leads to long-termdepression (LTD) of excitatory postsynaptic current (EPSC) amplitude
in GABAergic SNr neurons. This effect was absent in mGlu2 but not
mGlu3 knockout mice, indicating that activation of mGlu2 is essential
for induction of LTD in the SNr, with possible application of mGlu2
agonism for the treatment of the motor symptoms of PD (Johnson
et al., 2011). Non-selective group III agonists are effective in preclinical
PD models. The mGlu8 agonist DCPG (Thomas et al., 2001), adminis-
tered by intracerebroventricular route, showed robust reversal of
prolonged, but not acute, haloperidol-induced catalepsy and reserpine-
induced akinesia (Johnson et al., 2013). Further, DCPGadministrationde-
creased forelimb use asymmetry in unilateral 6-OHDA lesioned rats. This
evidence supports a role for mGlu8 agonism in potential PD treatment.
Therefore, the development of mGlu2 and mGlu8 PAMs may provide
therapeutic beneﬁt in PD.Fragile X syndrome and autism spectrum disorders
Fragile X syndrome (FXS) is an X-linked monogenic disorder, and is
the most common form of human inherited intellectual disability and
inherited cause of autism (Santoro et al., 2012). The brains of patient's
with FXS appear normal on gross examination, yet microscopically the
dendritic spines demonstrate an elongate immature phenotype. Pa-
tients with FXS have poor motor coordination, tactile hypersensitivity,
loose bowel movements, and an increased incidence of epilepsy. These
individuals have mental disability that includes attention deﬁcit
hyperactivity, obsessive–compulsive behaviors and labile mood. FXS is
most often caused by a trinucleotide repeat expansion (CGG) in 5′
untranslated region of the Fragile X mental retardation 1 (FMR1) gene,
leading to hypermethylation and vastly decreasing or silencing the ex-
pression of the fragile X mental retardation protein (FMRP). FMRP re-
presses translation of speciﬁc mRNAs (Bear et al., 2004) and is located
in the postsynaptic region of glutamatergic synapses. Interestingly,
FMRP inhibits translation of key proteins in the CNS that are stimulated
by mGlu1 and mGlu5 (Bhakar et al., 2012). FMRP plays a critical role in
long-term depression and other forms of synaptic plasticity. The ab-
sence of FMRP expression results in increased constitutive mGlu5 sig-
naling and subsequent “excessive” mGlu5-mediated protein synthesis
in post-synaptic dendrites with resulting dysregulation of synaptic
function. Generation of Fmr1 knockout mice with decreased mGlu5 ex-
pression (50%) showed improvement inmany rodent phenotypes asso-
ciated with Fragile X, including rescue of neuronal spine density,
supporting increased activity of mGlu5 as a key component in disease
development (Dolen et al., 2007). The mammalian target of rapamycin
(mTOR) pathway and the ERK pathway are implicated in the coupling
of mGlu5 to the translational complex (Bhakar et al., 2012). The mGlu5
NAMs MPEP and fenobam improve fragile X phenotypes in animal
models of FXS. Furthermore, chronic pharmacological mGlu5 inhibition
with CTEP in the Fmr1 knockoutmouse correctedmany features of frag-
ile X in adult mice (Michalon et al., 2012). These ﬁndings highlight the
importance of mGlu5 in FXS, and raise the possibility that constitutive
activity of mGlu5 may be important in FXS. Therefore, the inverse
agonist activity of mGlu5 NAMs, such as is observed for MPEP, may
be important for mGlu5 NAM efﬁcacy in this disease. Further studies
comparing compounds with and without inverse agonist activity will
determine the importance of mGlu5 constitutive activity in FXS. These
ﬁndings show promise for chronic mGlu5 NAM treatment of patients
with the FXS phenotype. A number of mGlu5 NAMs are now being in-
vestigated in clinical studies for efﬁcacy in treatment of FXS as well as
other indications (Bhakar et al., 2012; Emmitte, 2013). In a small clinical
trial of 30 fragile X patients, themGlu5 NAMAFQ056 (Novartis) showed
improvement in patients with full methylation of the FMR1 promoter
region, demonstrating that epigenetic modiﬁcation of the promoter
may determine responsiveness to mGlu5 NAMs (Jacquemont et al.,
2011; van Bon et al., 2011). Using lymphoblastoid cell lines from FXS
patients, treatment with AFQ056 did not induce demethylation of the
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(Tabolacci et al., 2012).
In addition to potential utility in the treatment of FXS, recent studies
raise the possibility that mGlu5 NAMs may also be useful for the treat-
ment of a broader range of autistic spectrum disorders, including idio-
pathic autism (Silverman et al., 2012). However, preclinical studies in
mice bearing mutations that lead to tuberous sclerosis, another devel-
opmental autistic spectrum disorder, suggest that mGlu5 NAMs could
exacerbate symptoms and that mGlu5 PAMs could have therapeutic
effects. Interestingly, tuberous sclerosis complex (TSC) patients often
have associated symptoms similar to Fragile X patients, including
epilepsy, autism spectrum disorders, and mental disability (Tsai and
Sahin, 2011). TSC mice treated with an mGlu5 PAM showed reversal
of cognitive defects, supporting a potential role for mGlu5 in TSC
(Auerbach et al., 2011). Thus, it will be critical to carefully consider spe-
ciﬁc patient populations and to develop amore complete understanding
of the potential impact of mGlu5 modulators in different childhood de-
velopmental disorders. FXS and TSC serve as valuable models to under-
stand the neurobiology behind genetically complex developmental
brain disorders and the potential impact of different genotypes on ther-
apeutic response to mGlu5 modulators (Krueger and Bear, 2011).
In addition to potential utility ofmGlu5modulators, it is important to
note that the early studies suggest that the signaling by bothmGlu5 and
the closely related mGlu1, are equally impacted by mutations that lead
to FXS (Bhakar et al., 2012). Thus, mGlu1 NAMs could also provide efﬁ-
cacy in FXS patients. While mGlu1 has received less attention than
mGlu5 as a potential target for the treatment of FXS, Thomas et al.
(Thomas et al., 2012) recently reported that selective mGlu1 NAMs
have robust efﬁcacy in reversing multiple symptoms in FXS mice.
Thus, it will be important to understand the potential for selective
NAMs for both subtypes in treatment of FXS and related disorders.
Schizophrenia and anxiety disorders
Schizophrenia is a debilitating psychiatric disorder affecting approx-
imately 1% of the population across the globe. The manifestation of this
disorder includes a triad of symptom clusters: positive symptoms, neg-
ative symptoms, and cognitive impairment (Kim et al., 2009). Current
therapies for the treatment of psychosis (positive symptoms) in schizo-
phrenia patients focus on blockade of the D2 dopamine receptors, and
are severely limited by poor efﬁcacy as well as adverse side effects
(extrapyramidal motor symptoms and metabolic syndrome and sexual
dysfunction). These combined effects limit the successful therapeutic
window for the D2 antagonists, with patients frequently switching
drugs to maintain effective treatment of symptoms. Additionally,
some D2 antagonists only show partial efﬁcacy in some patients.
The ﬁnding that NMDA receptor channel blockers, including PCP, keta-
mine, and dizocilpine (MK-801), induce psychosis in human volunteers,
led to the hypoglutamatergic theory of schizophrenia (Javitt, 1987). In
addition, the administration of NMDA receptor antagonists to schizo-
phrenic patients exacerbates both cognitive and psychotic symptoms
(Lahti et al., 1995; Malhotra et al., 1997). Clinical trials using glycine
co-agonists, which enhance NMDA receptor function, in combination
with standard antipsychotic therapy show efﬁcacy in decreasing nega-
tive symptoms and increasing cognition in schizophrenic patients
(Coyle and Tsai, 2004).
There is a large body of evidence that Group II (mGlu2 and mGlu3)
agonists or mGlu2 PAMs provide effective action against the positive
symptoms, while mGlu5 PAMs may have efﬁcacy in reducing all symp-
toms clusters schizophrenia patients (Herman et al., 2012). ThemGlu2/3
agonists LY354740 and LY379268 have robust efﬁcacy in multiple
rodent models of antipsychotic-like activity (Chaki et al., 2013) for
both schizophrenia (Conn et al., 2008; Schoepp and Marek, 2002) and
anxiolytic disorders (Schoepp et al., 2003; Swanson et al., 2005). The
antipsychotic-like activity is likely to bemediated, at least in part by re-
duced glutamate release from presynaptic terminals on projectionsfrom the thalamus to the prefrontal cortex in rodents (Cartmell et al.,
1999; Marek, 2010; Moghaddam, 2004). Further, an early clinical
study with a selective mGlu2/3 agonist showed promising effects in a
phase II clinical trial in patients with schizophrenia (Patil et al., 2007).
Unfortunately, this efﬁcacy has not been reliably observed in subse-
quent clinical studies (Adams et al., 2013; Hopkins, 2013; Kinon et al.,
2011). Experiments using mGlu2 and mGlu3 knockout mice provide
strong evidence that the antipsychotic-like effects of mGlu2/3 agonists
in rodent models are mediated by the activation of mGlu2 (Fell et al.,
2008). However, it has not been possible to develop orthosteric agonists
that are highly selective for mGlu2 relative to mGlu3.
Efforts to develop selectivemGlu2 PAMs have been highly successful
andmultiple studies reveal thatmGlu2-selective PAMs have robust efﬁ-
cacy in rodent models of antipsychotic activity that are similar to those
observed with mGlu2/3 agonists (Benneyworth et al., 2007; Cartmell
et al., 1999; Galici et al., 2006; Lorrain et al., 2003; Moghaddam and
Adams, 1998). ADX71149, a highly selective mGlu2 PAM that is now
in clinical development for the treatment of schizophrenia and anxious
depression, met the primary objectives of safety and tolerability in
phase I studies and advanced to phase IIa clinical testing. While the re-
sults of this important study have not yet been published, preliminary
reports from part B of the Phase IIa study suggest that ADX71149 may
have efﬁcacy in reducing negative symptoms in a subgroup of schizo-
phrenia patients (http://www.addextherapeutics.com/investors/press-
releases/news-details/article/addex-reports-top-line-data-from-a-
successful-phase-2a-clinical-study-with-adx71149-in-schizophrenia/).
Activation of mGlu4 with positive allosteric modulators may also
provide a promising therapeutic avenue for schizophrenia and the
development of antipsychotic agents. The Group III mGlu4-preferring
orthosteric agonist LSP1-2111 showed dose-dependent inhibition of
amphetamine-induced hyperactivity (Wieronska et al., 2012) and re-
versal of MK-801 induced deﬁcits in novel object recognition in rats
(Wieronska et al., 2013), indicatingpotential effects on both thepositive
and cognitive symptoms of schizophrenia. Further, recent studies with
mGlu4 PAMs show promising results in animal models that are used
to predict antipsychotic effects (Slawinska et al., 2013a,b). For instance,
the brain-penetrant mGlu4 PAMs Lu AF21934 and Lu AF32615 showed
dose-dependent reduction of amphetamine-induced hyperactivity
and antagonism of 2,5-dimethoxy-4-iodoamphetamine (DOI)-induced
head twitch tests in wild type but not mGlu4−/− mice, supporting a
key role for mGlu4 in brain circuits involved in these behavioral models
(Slawinska et al., 2013a). The mechanism of action for mGlu4 in rodent
models of antipsychotic activity are not known but are likely to be
unrelated to the antiparkinsonian effects ofmGlu4 PAMs. Recent studies
suggest that antipsychotic actions of mGlu4 PAMs may parallel the ef-
fects ofmGlu2/3 receptor agonists andmGlu2 PAMs. For instance, activa-
tion of mGlu4 reduces transmission at the same thalamo-cortical
terminals in the prefrontal cortex that are modulated by activation of
mGlu2 (Zhang and Marek, 2007). In addition, activation of mGlu4 re-
duces excitatory transmission in midbrain dopamine neurons (Valenti
et al., 2005) and this could contribute to the antipsychotic-like effects
of mGlu4 agonists or PAMs.
In addition to mGlu2-selective PAMs, recent efforts suggest that
mGlu5-selective PAMs may have potential as a novel approach for the
treatment of schizophrenia. Activation of mGlu5 receptors is known to
enhance NMDA receptor function in multiple cell populations and has
excitatory effects that may work in concert with NMDA receptors to in-
crease activity in forebrain circuits that are thought to be important for
thepsychotomimetic effects of NMDA receptor antagonists (Brody et al.,
2004b; Kinney et al., 2003; Lecourtier et al., 2007). Additionally, mGlu5
receptors interact physicallywithNMDA receptors through intracellular
scaffolding proteins (Niswender and Conn, 2010). As noted above,
antagonists of NMDA receptors induce positive and negative symp-
toms, as well as deﬁcits in cognitive function in humans that are
similar to those observed in schizophrenia patients (Adler et al.,
1998; Halberstadt, 1995; Krystal et al., 1994; Malhotra et al., 1996;
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body of clinical and preclinical studies have led to the hypothesis
that reduced activity of NMDA subtypes of glutamate receptors or
brain circuits that are regulated by NMDA receptors may play an im-
portant role in the pathophysiology underlying schizophrenia (Conn
et al., 2009c; Field et al., 2011; Nicoletti et al., 2011). Furthermore,
multiple studies suggest that agents that enhance NMDA receptor sig-
naling could provide efﬁcacy in reducing the symptoms associated
with schizophrenia (Coyle, 2006; Lindsley et al., 2006). Based on this,
and the clear role of mGlu5 acting in tandem with NMDA receptors to
regulate transmission through glutamatergic circuits in forebrain re-
gions, selective activators of mGlu5 have been raised as a potential
novel treatment strategy for schizophrenia thatmay have efﬁcacy in re-
ducing both psychotic and negative symptoms aswell as providing pro-
cognitive activity (Conn et al., 2009c). Consistent with this, mGlu5 KO
mice show disrupted prepulse inhibition (PPI), a model of sensory
motor gating shown to be disrupted in schizophrenic patients (Brody
et al., 2004a; Kinney et al., 2003). In addition, themGlu5 NAMMPEP po-
tentiates PCP-induced psychotomimetic and cognition impairment in
animal models (Brody et al., 2004a; Campbell et al., 2004). Based on
these importantﬁndings,major effortswere launched to develop highly
selective mGlu5 PAMs. These efforts have yielded a large number of
structurally diverse highly selective mGlu5 PAMs and multiple studies
have demonstrated that mGlu5-selective PAMs have robust efﬁcacy in
rodent models of schizophrenia that predict efﬁcacy in reducing both
positive and negative symptoms (Conn et al., 2009c; Liu et al., 2008;
Schlumberger et al., 2009, 2010). In addition, mGlu5 PAMs potentiate
multiple forms of synaptic plasticity that are thought to underlie specif-
ic aspects of learning and memory (Ayala et al., 2009; Liu et al., 2008;
Rosenbrock et al., 2010; Stefani and Moghaddam, 2010), and improve
cognitive function in multiple animal models (Darrah et al., 2008;
Stefani and Moghaddam, 2010; Vardigan et al., 2010). These exciting
studies suggest that mGlu5 PAMs have the potential to provide a funda-
mental advance in schizophrenia therapy that could have efﬁcacy in the
treatment of all major symptom clusters of the disease.
While the more subtle approach to modulation of glutamatergic
function usingmGlu5 PAMs has the potential to provide less adverse ef-
fect liability than would be observed with direct agonists of mGlu5 or
NMDA receptors, recent studies reveal that some mGlu5 PAMs induce
severe seizure activity (Rook et al., 2013) and excitotoxicity leading to
cell death in the auditory cortex, hippocampus, and other forebrain re-
gions (Parmentier-Batteur et al., in press). However, other mGlu5
PAMs are well tolerated and it is clear that all mGlu5 PAMs do not
have the same adverse effect liability (Rook et al., 2013). This suggests
that mGlu5 PAMs likely differ in their effects on mGlu5 signaling
and understanding these differences and the mechanistic underpin-
nings of mGlu5 PAM-mediated toxicity will be critical for fully devel-
oping mGlu5 PAMs as potential therapeutic agents. One property
that has been shown to play an important role in determining
whether speciﬁc mGlu5 PAMs will induce seizures and behavioral
convulsions is the presence or absence of allosteric agonist activity
(Rook et al., 2013). Of note, allosteric agonism is context dependent
and can be inﬂuenced by differences in receptor expression. For ex-
ample, Rook et al. (2013a,b) recently reported that the mGlu5 PAM
VU0424465 showed intrinsic agonist activity both in cell lines and
in native systems, while a group of closely related compounds
displayed agonist activity only in overexpressing cell lines and
others showed no detectable allosteric agonist activity in any cell
lines or native systems examined. Interestingly, VU0424465 showed
adverse effects, including epileptiform activity, while the related
compounds that were devoid of allosteric agonist activity in native
systems did not (Rook et al., 2013). These adverse effects are dose-
dependent and showed increased severity over time. These ﬁndings
highlight the importance of selecting mGlu5 PAMs lacking detectable
intrinsic (glutamate-independent) agonist activity to avoid
glutamate-independent receptor activity and the associated sideeffects. Also, as discussed above, mGlu5 PAMs and other GPCR allo-
steric modulators can regulate speciﬁc aspects of mGlu5 signaling
without affecting others (Noetzel et al., 2013; Zhang et al., 2005). It
is possible that some mGlu5 PAMs have greater effects on signaling
pathways that are involved in the adverse effect liability and that
those that are biased towards other pathways could provide efﬁcacy
without the severe adverse effect liability. In addition to these differ-
ent properties, recent studies suggest that hepatic metabolism of
some mGlu5 PAMs can yield metabolites that have robust activities
that differ from activity of the parent compound and can contribute
to the adverse effect liability (Bridges et al., 2013). In future studies,
it will be critical to gain a clear understanding of the mechanisms un-
derlying the different safety proﬁles of differentmGlu5 PAMs. Interest-
ingly, in a developmental model of schizophrenia (neonatal PCP-
induced cognition impairment), administration of mGlu5 PAMs in ad-
olescence prevented the appearance of delayed cognitive deﬁcits in
adult rats. Further, mGlu5 PAM administration reversed the delay-
induced impairment in adult rats, as evaluated by social novelty dis-
crimination (Clifton et al., 2013). These ﬁndings suggest the exciting
possibility of a preventative role for mGlu5 PAM treatment in the
development of schizophrenia, and further work will be important
to evaluate these ﬁndings.
Addiction
Glutamatergic neurotransmission is hypothesized to play a key role
in both establishment and maintenance of drug addiction (Nicoletti
et al., 2011). Negative allosteric modulators of Group I (mGlu1 and
mGlu5) mGlu receptors have potential as therapeutic agents for the
treatment of addictive disorders (Achat-Mendes et al., 2012; Bird and
Lawrence, 2009). The mGlu5 receptors are highly expressed in the
mesolimbic areas, regions central to the brain reward system. Mutant
mGlu5 null mice do not self-administer cocaine or exhibit locomotor-
stimulating effects, despite normal levels of dopamine in the nucleus
accumbens, supporting a role for mGlu5 in addiction (Chiamulera
et al., 2001). MPEP and MTEP treatment (mGlu5 NAMs) show efﬁcacy
in cocaine abuse rodent and non-human primate models (Kenny et al.,
2005; Kumaresan et al., 2009; Lee et al., 2005; Platt et al., 2008). Addi-
tionally, the novel mGlu5 NAM VU0463841 shows activity in a rat
model of cocaine addiction, with dose-dependent reduction of cocaine
place preference and cocaine self-administration (Amato et al., 2013).
Recently, mGlu1 antagonism (mGlu1 antagonist JNJ16259685) was re-
ported to inhibit cocaine-induced conditioned place preference (CPP)
through inhibition of protein synthesis in the ventral tegmental areas
(VTA) (Yu et al., 2013).
In addition to Group I antagonists, experimental evidence suggests a
potential role formGlu2 in addictive disorders. Cocaine reinforcement is
elevated in mGlu2 knockout mice, supporting the concept that mGlu2
negatively regulates the drug reward system (Morishima et al., 2005).
mGlu2/3 agonism is associated with decreased nicotine and cocaine
self-administration (Adewale et al., 2006; Liechti and Markou, 2007),
providing opportunity for the development of mGlu2/3 (likely mGlu2-
selective) PAMs for addiction.
Major depressive disorder (MDD)
Major depressive disorder (MDD) represents one of the most com-
mon forms of mental illness and is a signiﬁcant ﬁnancial and social bur-
den (Chaki et al., 2013). Monoamine oxidase inhibitors and tricyclic
antidepressants are the current mainstays of therapy for depression
and show slowonset of action aswell as poor efﬁcacy. A subgroup of pa-
tients are resistant to therapy, termed treatment resistant depression
(TRD). Ketamine, a noncompetitive (orthosteric)NMDA receptor antag-
onist, has shown considerable efﬁcacy for treatment-resistant depres-
sion in a double blind placebo controlled trial (Zarate et al., 2006).
Additional evidence of the role of hyperfunction of the glutamatergic
Table 1
Potential application of metabotropic (mGlu) and muscarinic (mACh) allosteric modulators in CNS diseases.
Receptor MOA CNS disease applications Compounds
mGlu1 NAM Neuropathic pain, FXS, anxiety/stress disorders, addiction CPCCOEt (Annoura H et al., 1996), JNJ16259685 (Lavreysen et al., 2004; Thomas et al., 2012)
PAM N/A Ro67-7476 (Knoﬂach et al., 2001), VU71(Hemstapat et al., 2006), Ro67-4853
(Wichmann et al., 2002), VU48 (Hemstapat et al., 2006)
mGlu5 NAM Addiction, anxiety, chronic pain, depression, FXS
(autism spectrum disorders), migraine, PD-LID,
MPEP (Gasparini et al., 1999), MTEP (Cosford et al., 2003), CTEP (Lindemann et al., 2011),
Fenobam (Porter et al., 2005), AFQ056 (Jacquemont et al., 2011); M-5MPEP (partial NAM),
Br-5MPEPy (partial NAM)(Rodriguez et al., 2005); GRN-529 (Hughes et al., 2013), VU046381
(Amato et al., 2013), RG7090 (RO4917523, antagonist, in clinical trials, FXS,
http://clinicaltrials.gov/ct2/results?term=RO4917523)
PAM Anxiety disorders, Huntington's disease, schizophrenia, TSC ADX47273 (Liu et al., 2008),
VU0360172 (Rodriguez et al., 2010),VU29 (Ayala et al., 2009), LSN2463359
(Gastambide et al., 2013; Gilmour et al., 2013)
mGlu2/3 NAM Depression RO4432717 (Goeldner et al., 2013), MNI-137 (Hemstapat et al., 2007)
mGlu2-selective PAM Addiction, AD, anxiety disorders, depression, schizophrenia BINA (Benneyworth et al., 2007; Galici et al., 2006), LY487379 (Johnson et al., 2003),
ADX71149 (Hashimoto et al., 2013)
NAM Depression MNI-167, RO4988546, RO5488608, RO4491533, RO4491533
mGlu3-selective NAM Depression VU0463597/ML-289 (Shefﬂer et al., 2012)
mGlu4 PAM Neuroinﬂammation, neuroprotection, PD, schizophrenia PHCCC (Maj et al., 2003; Marino et al., 2003), VU0155041 (PAM/allosteric agonist)
(Niswender et al., 2008), VU0364770 (Jones et al., 2012a), ADX88178 (Celanire and Campo, 2012),
Lu AF21934 (Slawinska et al., 2013a,b), Lu AF32615 (East et al., 2010)
mGlu7 NAM Anxiety, depression MMPIP (Hikichi et al., 2010; Niswender et al., 2010) and ADX71743 (Kalinichev et al., 2013)
Allosteric agonist Anxiety, depression, PD AMN082 (Ugolini et al., 2008)
mGlu8 Agonist Parkinson's disease, anxiety DCPG (Thomas et al., 2001)
M1 PAM AD, addiction, movement disorders, neuropathic pain, PD,
schizophrenia
Brucine (Lazareno et al., 1999), BQCA (Shirey et al., 2009), PQCA (Uslaner et al., 2013), ML-137
(Bridges et al., 2010c), ML-169/VU0405652 (Bridges et al., 2010e)
Allosteric agonist AD, movement disorders AC-42 (Spalding et al., 2002), N-desmethylclozapine (Sur et al., 2003), TBPB (Jones, Brady et al., 2008),
77-LH-28-1(Langmead et al., 2008a), VU0184670, VU0357017 (Digby et al., 2012a; Lebois et al., 2010),
VU0364572 (Digby et al., 2012b)
M4 M4-selective antagonist Dystonia, PD Tropicamide (Betz et al., 2007)
PAM AD, addiction, movement disorders, neuropathic pain, OCD,
PD, schizophrenia
Thiochrome (Lazareno et al., 2004), VU152099 (Brady et al., 2008), VU152100 (Brady et al., 2008),
LY2033928 (Chan et al., 2008), ML173 (Bridges et al., 2010d), ML293 (Shefﬂer et al., 2012)
M5 NAM Addiction, anxiety disorders, schizophrenia N/A
PAM Anxiety disorders, ADHA, PD, schizophrenia, VU0238429 (Bridges et al., 2009) (Bridges et al., 2010b)
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in plasma and limbic brains areas are elevated in depressed patients
(Sanacora et al., 2004). Modulation of glutamatergic transmission, par-
ticularly with mGlu2/3 agonists (Feinberg et al., 2002; Fell et al., 2011),
mGlu2/3 antagonists (Campo et al., 2011; Chaki et al., 2004; Palucha-
Poniewiera et al., 2010), and mGlu5 antagonists (Belozertseva et al.,
2007; Campo et al., 2011; Chaki et al., 2013; Li et al., 2006; Palucha
et al., 2005; Pilc et al., 2013) shows promising effects as potential treat-
ments for depression. Recently, the novelmGlu5 NAMGRN-529 showed
efﬁcacy in multiple rodent models of depression, including those rele-
vant to anxiety and pain, symptoms often associated with treatment
resistant depression (Hughes et al., 2013). Furthermore, fenobam
had efﬁcacy in reducing anxiety in a clinical proof-of-concept study
(Pecknold et al., 1982; Porter et al., 2005). Currently, themGlu5 antago-
nist RG7090 is in a phase II study for adjunctive therapy in patients with
major depressive disorder (MDD) (www.clinicaltrials.gov).
Additional CNS therapeutic areas for mGlu allosteric modulators
The allostericmodulators ofmGlu receptors havemany other poten-
tial uses including pain, stress/anxiety disorders, and movement disor-
ders (see Table 1) (Nicoletti et al., 2011). Neuropathic pain is a chronic
condition that leads to allodynia and hyperalgesia (Schkeryantz et al.,
2007). The mGlu1 receptor is expressed in CNS regions essential to
nociceptive processing as well as in afferent nociceptive nerve termi-
nals (Martin et al., 1992). mGlu1 knockout mice show decreased pain
sensitivity (Schkeryantz et al., 2007) and administration of the
mGlu1-selective NAM JNJ16259685 (Lavreysen et al., 2004) is re-
ported to show efﬁcacy in a rodent neuropathic pain model (forma-
lin hyperalgesia) (Mabire et al., 2005). Additionally, mGlu1-selective
antagonists showed in vivo activity in the spinal nerve ligation test
(Bennett et al., 2012). Taken together, the development of mGlu1-
selective NAMs (Annoura H et al., 1996; Mabire et al., 2005) and ef-
ﬁcacy in preclinical models are promising for the potential treatment
of neuropathic pain. mGlu5 NAMs show analgesic efﬁcacy in preclin-
ical models of neuropathic pain (Kumar et al., 2010; Montana et al.,
2009). Agonists of mGlu 2/3 receptors also show analgesic effects in
models of chronic and neuropathic pain, but show tolerance after
chronic treatment (Jones et al., 2005).
In addition tomGlu4, subtype-selective allosteric modulators for the
other Group III mGlu receptors (mGlu7 and mGlu8) may also have po-
tential for the treatment of CNS disorders. Recently, the mGlu7 NAMs
MMPIP (Hikichi et al., 2010) and ADX71743 (Kalinichev et al., 2013)
have shown potential efﬁcacy in animal models for the treatment of
anxiety and depression, and provide excellent tool compounds to fur-
ther elucidate the role of mGlu7 in CNS diseases. As described above,
the mGlu8 agonist DCPG (Thomas et al., 2001) showed efﬁcacy in pre-
clinical models of PD (Johnson et al., 2013), and the development of
mGlu8 selective PAMs may provide novel therapeutics for PD patients.
Recently, mGlu5 PAMs showed neuroprotective effects in the BACHD
mousemodel of Huntington's disease (Doria et al., 2013). The continued
development of mGlu allosteric modulators provides promising tools
for the investigation of the role of individual receptor subtypes in CNS
disease and the creation of novel therapeutics for an array of CNS
disorders.
Muscarinic acetylcholine receptors
Allosteric modulators of muscarinic receptors show promise as po-
tential therapies for a number of CNS disorders, including Alzheimer's
disease and schizophrenia. Other target areas of beneﬁt may include
neuropathic and chronic pain, epilepsy, sleep disorders, Parkinson's
disease, and movement disorders (Conn et al., 2009b). Acetylcholine
signals through both muscarinic and nicotinic receptors. Muscarinic
acetylcholine receptors are widely expressed in the CNS and include
ﬁve subtypes (M1–M5) (see Langmead et al., 2008b for review). TheseFamily A GPCRs respond to the endogenous agonist acetylcholine and
are further subdivided into two groups based on signaling pathways.
TheM1,M3, andM5 receptors signal throughGq/11, activating PLCβ lead-
ing to increased intracellular calcium. The M2 and M4 receptors signal
through Gi/o proteins and inhibit adenylate cyclase. Also, M2 andM4 sig-
naling throughGiβγ subunitsmodulates ion channel activity.Muscarinic
acetylcholine receptors (mAChRs) are expressed throughout the CNS,
including targets for cholinergic interneurons in the striatum as well
as targets of projections from the medial septum and hindbrain nuclei
in the, midbrain, neocortex and limbic areas important for learning
and memory. Both the M1 and M4 receptors are associated with learn-
ing, memory and cognition (Hasselmo, 2006; Hasselmo and Giocomo,
2006), and drugs speciﬁc for these subtypes may be useful in treat-
ment of the cognitive symptoms associated with schizophrenia and
Alzheimer's disease. The orthosteric acetylcholine (ACh) binding site is
highly conserved, thwarting attempts to create an orthosteric drug
with true subtype selectivity. Drugs developed for the orthosteric site
lack subtype speciﬁcity and result in dose-dependent adverse side
effects (bradycardia, sweating, salivation and gastrointestinal distress)
from activation of the peripheral M2 and M3 mAChR subtypes (Heinrich
et al., 2009).
Alzheimer's disease
Alzheimer's disease represents a major public health problem as the
world population ages in the coming decades. The features of this pro-
gressive neurodegenerative disease include neuronal loss, behavioral
and cognitive changes and decreased cerebral blood ﬂow (Bartus
et al., 1982;Hanyu et al., 2003). Acetylcholine receptor agonists and ace-
tylcholinesterase (AChE) inhibitors improve the cognitive symptoms in
Alzheimer disease patients (Feldman, 2002; Grossberg, 2002) and AChE
inhibitors are among the fewmedications available for the treatment of
AD. These cholinergic agents have limited efﬁcacy and induce peripher-
al side effects, which limit their use (Lockhart et al., 2009). Studies have
suggested that activation of muscarinic acetylcholine receptors may
prove useful in the treatment of multiple symptoms in the spectrum
of both Alzheimer's disease and schizophrenia (Langmead et al.,
2008b). The muscarinic receptor orthosteric agonist xanomaline (M1
and M4 selective) has been shown to be effective in reducing the psy-
chotic symptoms in patients with both schizophrenia and AD. A phase
III placebo-controlled clinical trial showed that xanomeline robustly de-
creased psychotic symptoms in patients with Alzheimer's disease
(Bodick et al., 1997a,b). While improved cognition was observed for
those patients who completed the trial (high dose vs. placebo), the
end-point analysis was not statistically signiﬁcant for cognitive im-
provement. The main limiting side effect of xanomeline involved gas-
trointestinal associated symptoms (Bodick et al., 1997b). This study
demonstrates that muscarinic agonists have potential in treating both
the cognitive and behavioral aspects of Alzheimer's disease.
Both M1 and M4 allosteric agonists and PAMs would be desirable
drug candidates for therapeutic development. The M1 receptor is
expressed in high levels in the CNS, particularly the cortex, hippocam-
pus, and striatum (Levey et al., 1991, 1995). Efforts have focused on
the development of M1 speciﬁc ligands for AD, as M1 is thought to be
the critical subtype for cognition, attention, and sensory processing
(Fisher, 2008; Langmead et al., 2008b; Robinson et al., 2011). Addition-
ally, M1 knockout mice show speciﬁc cognitive deﬁcits (Anagnostaras
et al., 2003; Miyakawa et al., 2001). For M1 selective orthosteric ago-
nists, the lack of true selectivity for M1, coupled with high receptor re-
serve of M2 and M4 in native tissues, results in functional activity at
multiple receptor subtypes, with unacceptable side effect proﬁles. For
example, the orthosteric agonist AF267, thought to have subtype speci-
ﬁcity for M1, showed activity at both M3 and M5 receptors (Jones et al.,
2008). CurrentM1/M4 selective muscarinic orthosteric ligands show in-
tolerable side effects related to their lack ofmuscarinic receptor subtype
selectivity. The development of muscarinic allosteric modulators has
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tential to minimize peripheral muscarinic side effects.
Brucine, the ﬁrst M1 PAM identiﬁed, provided proof-of-concept
for the development of M1 subtype speciﬁc ligands (Lazareno et al.,
1998). A functional screening approach identiﬁed novel M1 PAMs, in-
cluding VU0090157 and VU0029767, that showed pure PAM activity
(Marlo et al., 2009) and could differentially regulate coupling to differ-
ent signaling pathways. The systemically active M1 PAM BQCA induces
an increase in activation of the prefrontal cortex (PFC) and improves
PFC-dependent cognitive function in a transgenic mouse model of PD
(Shirey et al., 2009). In addition, BQCA has activity in other models
that suggest possible efﬁcacy in improving cognitive function and re-
ducing psychotic symptoms (Ma et al., 2009). Recently, the M1 PAM
PQCA was shown to improve cognitive function in non-human pri-
mates, including improvements in the object retrieval detour task in
rhesusmacaques. Further, PQCA treatment increased frontal cortical ce-
rebral blood ﬂow at parallel drug concentrations, providing a potential
translational biomarker for future studies (Uslaner et al., 2013). The
continued development and optimization of M1 PAMs, such as ML137,
are providing exciting tools for investigative efforts into the role of M1
in CNS disorders (Melancon et al., 2013; Poslusney et al., 2013).
Additionally, M1 selective allosteric agonists have been developed,
including AC-42 (Spalding et al., 2002), N-desmethylclozapine (Sur
et al., 2003), TBPB (Jones et al., 2008) and 77-LH-28-1 (Langmead
et al., 2008a). The M1 allosteric agonist AC260584 shows antipsychotic
activity in preclinical models (Vanover et al., 2008), but also is active
at the 5-HT2A serotonin receptor, D2 dopamine receptor and α1A adren-
ergic receptor (Heinrich et al., 2009). The recently developed selective
allosteric agonists VU0357017 and VU0364572 showed robust efﬁcacy
in a rodent hippocampal dependent learning paradigm (Lebois et al.,
2010). A number of M1 allosteric agonists show bitopic binding (binds
to both an allosteric site and the orthosteric site), including 77-LH-28-1
(Lebon et al., 2009), AC-42 (Spalding et al., 2002), and VU0364572
(Digby et al., 2012b). These allosteric agonists provided valuable tools
for the investigation of M1 in AD, but are limited by activity at other
GPCRs and show complicated pharmacology with their bitopic mode of
action. Furthermore, selectivity of these compounds is based on func-
tional selectivity. Issues with high receptor reserve have made it
difﬁcult to maintain high selectivity while both optimizing for maximal
M1 potency and efﬁcacy and achieving drug-like properties of highly
selective M1 allosteric agonists (Digby et al., 2012b).
In addition to acute actions on cognitive function, activation of M1
reduces the pathological processing of amyloid precursor protein
(APP) associated with Alzheimer's disease. TBPB, a systemically active
M1 allosteric agonist, shows decreased production of βAPP (Jones
et al., 2008) and the M1 agonist AF267B shifts APP towards the non-
amyloidogenic pathway (Caccamo et al., 2006; Jones et al., 2008). Addi-
tionally, M1 agonists show evidence of decreasing CSF Aβ42 levels in
AD patients (Fisher, 2008; Heinrich et al., 2009). Therefore, drugs that
activate AChRs may have disease modifying properties in AD as well
as improve cognitive function.
Schizophrenia
The ﬁnding that the M1/M4 preferring orthosteric agonist
xanomeline has antipsychotic-like effects in AD patients raises the
question of whether M1 and/or M4 activation could also have efﬁcacy
in reducing psychotic symptoms in patients suffering from schizophre-
nia. The surprising ﬁnding of antipsychotic efﬁcacy of xanomeline in AD
patients prompted a Phase II clinical trial to evaluate antipsychotic
efﬁcacy of xanomeline in schizophrenia patients (Shekhar et al.,
2008). Interestingly, xanomeline improved positive, negative, and cog-
nitive symptoms in patients suffering from schizophrenia (Shekhar
et al., 2008). This ﬁnding is especially interesting in light of previous
studies showing that muscarinic receptor antagonists worsen symp-
toms in schizophrenic patients (Tandon et al., 1991) and producepsychotic symptoms in some individuals not suffering from schizophre-
nia or related disorders (Osterholm and Camoriano, 1982). Further-
more, analysis of postmortem brain samples from schizophrenic
patients show decreased levels of M1/M4 receptor binding in key brain
regions implicated in the disease, including the prefrontal cortex,
superior temporal gyrus, hippocampus, and dorsal striatum (Crook
et al., 2000; Dean et al., 2002; Deng and Huang, 2005; Zavitsanou
et al., 2004). Taken together, these data raise the exciting possibility
that M1 and/or M4 PAMs may also have potential utility in treatment
of schizophrenia.
TheM4 receptor is expressed in numerous areas of the brain includ-
ing the cortex, striatum, and hippocampus (Levey et al., 1995). M4 colo-
calizes with the D1 receptor in the striatum (Ince et al., 1997),
suggesting a balance between cholinergic and dopaminergic neuro-
transmission. Mutant mice with knockout of M4 in D1 dopamine ex-
pressing cells (D1-M4-KO) do not show an antipsychotic response to
xanomeline in rodent models of schizophrenia, highlighting the poten-
tial importance of M4 receptors in schizophrenia (Dencker et al., 2011).
Xanomeline treatment attenuates amphetamine-induced hyperactivity
in M1 knockout mice, and completely inhibits the effects of amphet-
amine inM4 knockoutmice, suggesting a greater role for M4 in this pro-
cess (Woolley et al., 2009). Development of the initial M4 PAM
thiochrome showed proof-of-concept for designing compounds with
M4 subtype selectivity (Lazareno et al., 2004). The discovery of a highly
selective M4 PAM, VU10010 (Shirey et al., 2008) and subsequent
development of centrally active M4 PAMs (VU0152099, VU0152100,
and VU0448088) demonstrated reversal of amphetamine-induced
hyperlocomotor activity in rats (Brady et al., 2008; Le et al., 2013).
The M4 PAM LY2033298 also showed efﬁcacy in rodent models of anti-
psychotic efﬁcacy, including conditioned avoidance responding and
prepulse inhibition (Chan et al., 2008). LY2033298 potentiated the ef-
fect of oxotremorine (nonselective muscarinic agonist)-mediated inhi-
bition of conditioned avoidance responding, indicative of antipsychotic
properties (Leach et al., 2010). The effect was reduced in M4 knockout
mice, supporting a potential role for M4 in models of schizophrenia. In-
terestingly, LY2033298 can have allosteric agonist activity under specif-
ic conditions as well (Chan et al., 2008; Nawaratne et al., 2010). These
data provide strong support for the hypothesis that the antipsychotic
effects of xanomeline are in part mediated by activation of M4 and
that highly selective M4 PAMs may provide a novel approach to devel-
opment of antipsychotic agents. In addition to potential efﬁcacy in
patients suffering from schizophrenia, M4 PAMs could also provide efﬁ-
cacy in reducing the psychotic symptoms observed in patients suffering
from AD and other neurodegenerative disorders.
Based on the discussion of M1 PAM actions in models of AD above, it
is possible thatM1 PAMs could also provide efﬁcacy in improving cogni-
tive function in schizophrenia patients. Interestingly, schizophrenic pa-
tients with an M1 genetic polymorphism (CHRM1) had more correct
responses with less perseverative errors in the Wisconsin Card Sorting
Test (Liao et al., 2003). In total, the data generated thus far favors a
prominent role ofM4 in psychotic symptoms andM1 as amajor contrib-
utor to speciﬁc domains of cognitive function. However, further studies
are needed to develop a full understanding of the respective roles of M1
and M4 in the clinical efﬁcacy of xanomeline and it is likely that M1
activity also contributes to the antipsychotic efﬁcacy and M4 to the
cognition-enhancing effects. The development of highly selective posi-
tive allosteric modulators for M1 and M4 receptors provides the tools
needed to develop this understanding. Furthermore, M1 and M4 PAMs
provide exciting new therapeutic opportunities to achieve subtype
speciﬁcity with minimal peripheral muscarinic side effects and shows
promise for the identiﬁcation of novel therapeutics for both Alzheimer's
disease and schizophrenia. Multiple companies are now focusing effort
on discovery and development of selective M1 PAMs for the treatment
of schizophrenia and Alzheimer's disease. The Vanderbilt Center for
Neuroscience Drug Discovery has now partnered with Astrazeneca
to advance M4 PAMs into clinical development (Jones et al., 2012b).
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sessment of the potential utility of M1 and M4 PAMs in AD and schizo-
phrenia in the coming years.
M1/M4 agonists also have potential therapeutic applications in
addiction and chronic neuropathic pain. The muscarinic receptors in
the brain play a key role in the development of addiction (Sofuoglu
and Mooney, 2009; Williams and Adinoff, 2008). M1/M4 muscarinic
agonists mediate the attenuation of cocaine self-administration and co-
caine discriminative stimulus, which is abolished in M1/M4 knockout
mice (Thomsen et al., 2010, 2012). Therefore, M1 and/or M4 agonism
is under investigation in the treatment of drug dependence and addic-
tion. M1/M4 agonists show efﬁcacy in chronic inﬂammatory and neuro-
pathic pain, with xanomeline showing analgesic effects in a chronic
inﬂammatory neuropathic pain rodent model (Martino et al., 2011).
M5 modulators
The M5 muscarinic receptor subtype comprises less than 2% of the
CNS muscarinic receptors, and is expressed in both the cerebrovascular
system and midbrain dopamine neurons (Weiner et al., 1990). The M5
receptor is the sole muscarinic subtype detected in the ventral tegmen-
tal area (VTA) and substantia nigra pars compacta (SNc) (Vilaro et al.,
1990; Weiner et al., 1990), where it is coexpressed with D2 dopamine
receptors, suggesting a role for M5 in the modulation of dopaminergic
transmission (Weiner et al., 1990). Modulation of dopaminergic func-
tion usingM5 PAMs or NAMs has been raised as having potential utility
in the treatment of addiction (Raffa, 2009) and could also have utility for
the treatment of other disorders that involve changes in dopaminergic
function, including schizophrenia, and attention-deﬁcit hyperactivity
disorder (ADHD). The combination of the genes for M5 (CHRM5)
and α7 nicotinic acetylcholine receptor show linkage with schizo-
phrenia susceptibility in humans (De Luca et al., 2004). Additionally,
the M5 knockout mouse shows decreased amphetamine-induced
hyperlocomotion (Wang et al., 2004). The localization of the M5
receptor to dopaminergic midbrain neurons and association with a
preclinical model of schizophrenia is encouraging for research into
the role of M5 in schizophrenia. Studies of M5 knockout mice suggest
that M5 may be a target in AD due to cerebrovascular tone regulation
(Yamada et al., 2001) as well as cognitive function. Until recently, no
selective M5 ligands existed, making it difﬁcult to fully evaluate the
potential utility of M5 modulators in animal models related to
these disorders. However, the recent discovery of highly selective
M5 PAMs (Bridges et al., 2009, 2010a) provides novel tools for the
investigation of the role of M5 in CNS disorders.
Potential utility of M4 NAMs in treatment of Parkinson's disease and dystonia
Historically anticholinergic agents were used as treatments in PD,
beginning with the deadly nightshade Atropa belladonna. The concept
of striatal dopaminergic–cholinergic antagonism developed with ﬁnd-
ings that with decreased dopamine in the striatum there is evidence
of increased acetylcholine levels in PD (Salamone et al., 2001). Anticho-
linergics in PD act through muscarinic receptors, and acetylcholinester-
ase inhibitors (such as physostigmine) are known to worsen PD
symptoms (Bourke and Druckenbrod, 1998; Ott and Lannon, 1992).
Drug-induced tremulous jaw movements serves as a recent model
for the resting tremor associated with Parkinson's disease. Tremulous
jaw movements induced by the muscarinic antagonist pilocarpine are
robustly decreased in M4 knockout mice, suggesting that the M4 sub-
type plays a key role (Salamone et al., 2001). Additionally, the M4-
preferring antagonist tropicamide inhibits tremulous jaw movements
in a rodent model of Parkinson's disease (Betz et al., 2007). Therefore,
there is therapeutic potential for use of M4 NAMs to control tremor
associated with PD. M4-targeted therapies have potential applications
in other movement disorders, including dystonia and Huntington's dis-
ease, where there is evidence of cholinergic dysfunction (Pisani et al.,2007; Smith et al., 2006). Also, muscarinic antagonists are among the
few agents that can provide efﬁcacy in treatment of generalized dysto-
nia (Jankovic, 2006; Martella et al., 2009). It is possible that highly
selective NAMs for M4 or another mAChR subtype could provide
antidystonic efﬁcacy without the adverse effects observed with non-
selective mAChR antagonists.
Optimization of allosteric modulators as drug candidates
Development and optimization of allosteric modulators of GPCRs as
drug candidates present multiple challenges (Conn et al., 2012; Klein
et al., 2013;Melancon et al., 2012). The success of lead compound devel-
opment for a number of allosteric modulators of GPCRs has established
a set of drug optimization strategies for this class. With the nonlinear or
“ﬂat/shallow” nature of SAR for many members of this drug class, de-
signing libraries around a central core by focusing on “islands” of con-
stituents has led to successful lead optimization (Nawaratne et al.,
2010; Wood et al., 2011). Also, it is critical to focus attention on both
SAR of potency and cooperativity of allosteric modulators as well as dif-
ferential effects on different aspects of receptor signaling (Wootten
et al., 2013). Attention to principals emerging frommedicinal chemistry
optimization of allostericmodulators increases the opportunities for ad-
vancing successful drug candidates in this class. Once a hit compound is
identiﬁed via high throughput screening, chemical tractability should
be established through the synthesis of appropriate focused iterative
compound libraries to generate lead compounds. The use of systematic
ﬂuorine substitution strategies has been successful for identifying ﬂuo-
rinated cores tolerant of change, and proved successful for M1 PAM de-
velopment (Bridges et al., 2010d; Reid et al., 2011; Yang et al., 2010).
Therefore, ﬂuorine substitution may prove a good ﬁrst tier strategy for
the optimization of hit compounds. Selecting hit compounds with the
combination of both tractable SAR and encouraging physicochemical
properties has proven successful (Kenakin andMiller, 2010). It is essen-
tial to fully characterize lead compounds using radioligand binding to
establish in vitro receptor interaction. Running multiple (secondary/
parallel) functional screens (such as GTPγS if primary screening
performed was FLIPR calcium assay) will help to avoid stimulus bias in
cases where biased ligands are not desired. In addition, allosteric mod-
ulators may show differential signaling depending on the cellular con-
text used for screening (Niswender et al., 2010). The use of in vitro
native systems, such as brain slice electrophysiology, supports biological
relevance of lead compounds. It is also important to note that the choice
of orthosteric compound is critical for allosteric modulator screening
and optimization efforts, as the cooperativity between the allosteric
modulator and orthosteric site can change depending on the orthosteric
probe ligand, a concept termed “probe dependence” (Kenakin, 2005;
May and Christopoulos, 2003). Use of the endogenous orthosteric ligand
increases the likelihood of physiological relevance. Screening assays
using non-native agonists should be interpreted with the caveat of
probe-dependent pharmacology. Additionally, allosteric sites vary across
species and may lead to differences between in vitro screens and in vivo
animal model pharmacology.While cell line systems that allow relative-
ly high throughput are critical for screening compounds in a chemistry
program, it is critical to be mindful that there are instances in which
there is a disconnect between effects of allosteric modulators in cell
based assays and in biologically relevant native systems and in vivo as-
says. The differences in pharmacology observed in cell based assays as
compared to native systems can stem from undetected stimulus bias,
or context-dependence of allostericmodulator action and canmake allo-
steric modulator optimization especially challenging. This can be further
complicated by “molecular switches” in which subtle changes to the
structure of a compound changes themode of pharmacology of allosteric
modulators (i.e. mode switching with PAM to NAM/SAM conversion
with subtle structural changes) and/or changes the receptor subtype se-
lectivity can confound lead compound development (Bhagwanth et al.,
2012; Gregory et al., 2013; Melancon et al., 2012; Utley et al., 2011;
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compounds have a limited ability to detect weak or partial allosteric
modulators, which may prove to be useful compounds for further
development (Christopoulos and Kenakin, 2002). This is especially
important when metabolites of administered allosteric modulators
have pharmacological activity that is different from that of the parent
compound and thereby confound interpretation of in vivo effects of sys-
temically administered allosteric modulators (Bridges et al., 2013). It is
recommended to use compounds of the same chemotype and demon-
strate competitive interactions with test compounds for both ex vivo
occupancy studies and in vivo imaging studies. In summary, the drug
discovery effort for allosteric modulators has provided valuable insight
into optimal methods for hit-to-lead development. While the complex
pharmacology of mode switching, functional bias and bitopic ligand
activity complicate the discovery process for allosteric ligands, they
provide novel insight into the function of GPCRs. In fact, functional
selectivity may become an asset for allosteric modulators targeting
disease states linked to a speciﬁc signaling pathway.
Future opportunities
Allosteric modulators of GPCRs represent exciting drug candidates
for the treatment of an array of CNS disorders. In addition to themetab-
otropic andmuscarinic allostericmodulators detailed above, drugs have
been developed targeting a number of other GPCRs (see Conn et al.,
2009a for review and AlloSteric database (http://mdl.shsmu.edu.cn/
ASD/)) (Huang et al., 2011). Several drugs have successfully entered
the marketplace, providing proof of concept for allosteric modulators
as clinical therapeutics. Cinacalcet (Sensipar), a PAM for the calcium
sensing receptor (CaSR), is currently used to treat patients with hyper-
parathyroidism (Davey et al., 2012; Nemeth et al., 2004). Maraviroc
(Selzentry), a NAM of chemokine receptor 5 (CCR5) (Garcia-Perez
et al., 2011), prevents HIV-1 cellular entry. In addition to GPCRs, alloste-
ric modulators have also been developed for enzymes including alloste-
ric kinase (Akt) inhibitors (Lindsley et al., 2005) and phospholipase D
(PLD) (Lavieri et al., 2010; Scott et al., 2009).
Advantages of allosteric modulators of GPCRs include subtype selec-
tivity and functional selectivity. With the emerging literature on signal-
ing bias, it may be possible to tailor allosteric development to target
speciﬁc downstream receptor pathways, avoiding undesirable side ef-
fects elicited by parallel signaling pathways. Due to the functional selec-
tivity possiblewith allosteric ligands, it is crucial to incorporatemultiple
functional assays into drug screening paradigms. Probingmultiple path-
ways will allow for early detection of pathway dependent allosteric
modulation (Conn et al., 2009a). The development and utilization of
the operational model of allosterism allows for characterization and
quantiﬁcation of allosteric drug properties. In addition, it may be possi-
ble to utilize partial or silent allosteric modulators to avoid adverse
effect liability. PAM ligands may also exhibit allosteric agonist activity,
termed ago-potentiators, a feature that may prove advantageous in
certain CNS diseases. As a part of drug development in the neurodegen-
erative and psychiatric area, there is increased emphasis on early
demonstration of in vivo target engagement using microPET imaging
in non-human primate models, with development of radioactive
ligands critical to this effort (Lee and Farde, 2006; Marik et al., 2011).
This PET data is especially important in the absence of speciﬁc disease
biomarkers, and can help with in vivo dose selection to avoid under
or overdosing. The surge in efforts to develop allosteric modulators of
GPCRs and the collaboration between industry and academics paints
a promising picture for the effort to develop effective treatments for
CNS diseases.
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